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The IL-6 Trans-Signaling-STAT3 Pathway Mediates
ECM and Cellular Proliferation in Fibroblasts from
Hypertrophic Scar
Sutapa Ray1,5,7, Xiaoxi Ju2, Hong Sun1, Celeste C. Finnerty4,5,6,7, David N. Herndon3,4,7 and
Allan R. Brasier1,2,5,6,7
The molecular mechanisms behind the pathogenesis of postburn hypertrophic scar (HS) remain unclear. Here,
we investigate the role of the IL-6 trans-signaling-signal transducer and activator of transcription (STAT)3 pathway
in HS fibroblasts (HSFs) derived from post-burn HS skin. HSF showed increased Tyr 705 STAT3 phosphorylation
compared with normal fibroblast (NF) after IL-6IL-6Ra stimulation by immunoassays. The endogenous STAT3
target gene, SOCS3, was upregulated in HSFs and showed increased STAT3 binding on its promoter relative to
NFs in a chromatin immunoprecipitation assay. We observed that the cell-surface signaling transducer
glycoprotein 130 is upregulated in HSFs by quantitative real-time reverse-transcriptase–PCR and flow cytometry.
The production of excessive extracellular matrix (ECM), including the expression of alpha2 (1) procollagen
(Col1A2) and fibronectin 1 (FN), was seen in HSFs. A STAT3 peptide inhibitor abrogated FN and Col1A2 gene
expression in HSFs indicating involvement of STAT3 in ECM production. The cellular proliferation markers Cyclin
D1, Bcl-Xl, and c-Myc were also upregulated in HSF, and knockdown of STAT3 by small interfering RNA attenuated
c-Myc expression indicating the essential role of STAT3 in fibroblast proliferation. Taken together, our results
suggest that the IL-6 trans-signaling-STAT3 pathway may have an integral role in HS pathogenesis, and disruption
of this pathway could be a potential therapeutic strategy for the treatment of post-burn HS.
Journal of Investigative Dermatology (2013) 133, 1212–1220; doi:10.1038/jid.2012.499; published online 10 January 2013
INTRODUCTION
Exuberant fibroproliferation leading to hypertrophic scar (HS)
is a common complication after thermal and other injuries for
reasons that are not well understood. HS is characterized by
erythematous, raised, pruritic lesions in the healing skin,
which significantly impair the quality of life in affected
patients (Deitch et al., 1983; Scott et al., 2000; Bombaro
et al., 2003). There is currently no definitive treatment
available for HS. Although interventions including skin
grafting, pressure therapies, steroids, and silicone dressings
have been tried with modest success, the only effective
treatment until now has been surgical removal (van Zuijlen
et al., 2001; Sheridan and Tompkins, 2004). One main
histological characteristic of HS is the hypercellularity
because of increased numbers of fibroblasts and the
recruitment of inflammatory cells, producing profibrogenic
factors to increase angiogenesis and abnormal extracellular
matrix (ECM) deposition (Castagnoli et al., 1997). Thus,
disruption of the balance between synthesis and degradation
of ECM during the remodeling phase of wound healing may
lead to abnormal scarring—resulting in HS.
Recent studies evidence that the IL-6 signaling pathway,
converging on JAK–signal transducer and activator of tran-
scription (STAT)-3 complex, is important for both wound
healing and in keloid pathogenesis (Lim et al., 2006;
Ghazizadeh et al., 2007). IL-6 is a multifunctional cytokine
that is upregulated in response to inflammation, oxidative
stress, vascular damage, and burn injuries (Finnerty et al.,
2006; Hou et al., 2008b). IL-6 production by inflammatory
cells and dermal fibroblasts has been linked to the
pathogenesis of fibrosis associated with rheumatoid arthritis,
systemic sclerosis, pulmonary interstitial fibrosis, and psoriatic
lesions (Tan et al., 1990; Feghali et al., 1994; Shahar et al.,
1996; Sano et al., 2008).
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IL-6 signals to responsive cells through a ‘‘classic’’
signaling pathway by binding cell-surface IL-6Ra or by
‘‘trans-signaling,’’ mediated by IL-6 and soluble IL-6Ra
(sIL-6Ra)-binding cell-surface glycoprotein 130 (gp130). In
the classic signaling pathway, binding of IL-6 to IL-6Ra
triggers formation of a membrane-bound hexameric IL-6IL-
Ragp130 high-affinity complex (Jones et al., 2001; Scheller
and Rose-John, 2006). Receptor ligation induces conforma-
tional changes in the cytoplasmic domains of gp130 that
bring JAKs into close proximity. Phosphorylation of gp130 by
JAKs then activates STATs, particularly isoforms-1 and -3.
Activated STAT3 rapidly translocates into the nucleus, where
it binds to enhancer sequences of genes that control
fundamental cellular processes, including acute phase
response, survival, proliferation, differentiation, and wound
healing (Kushner, 1988; Yamauchi-Takihara and Kishimoto,
2000; Dauer et al., 2005).
In contrast, the IL-6 trans-signaling pathway is mediated by
formation of a soluble IL-6sIL-6Ra complex that binds gp130
and activates STAT3 in any cell type, extending the actions of
IL-6 to cells that do not normally express IL-6Ra (Jones et al.,
2001; Vermes et al., 2002). The release of sIL-6Ra is known to
occur either by differential messenger RNA (mRNA) splicing
or by proteolytic cleavage mediated by activated leukocytes
(Ebihara et al., 2011). Remarkably, recent studies revealed that
the IL-6sIL-6Ra complex is induced in chronic inflammatory
diseases, especially Crohn’s disease, rheumatoid arthritis, and
inflammatory colon cancer, where it may be important in
disease maintenance (Jones et al., 2001).
Although studies on the human burn response show induction
of IL-6 secretion and acute-phase reactant synthesis (Jeschke et al.,
2008), the role of the IL-6 trans-signaling and activation of the
gp130-STAT3 pathway in mediating exaggerated scar formation
has not been explored. In this paper, we hypothesized a role for
the IL-6 trans-signaling pathway in HS formation and showed that
compared with normal fibroblasts (NFs), HS fibroblasts (HSFs)
show an exaggerated STAT3 response to IL-6sIL-6Ra, and
phosphorylated STAT3 caused induction of membrane-bound
gp130 expression. Finally, we show that excessive ECM synthesis
and cellular proliferation are suppressed by a cell-permeable
STAT3 peptide inhibitor and STAT3 small interfering RNA
(siRNA), respectively. Thus, these data reveal an indispensable
role of STAT3 downstream of the IL-6 trans-signaling pathway in
HS pathogenesis, and therefore STAT3 inhibition may serve as a
therapeutic target for the treatment of HS fibrosis.
RESULTS
Expression of phosphorylated STAT3 in postburn HS
To determine whether STAT3 participates in HS formation,
paraffin-embedded HS sections from recovering burn patients
were used to perform immunohistochemistry (IHC) analysis
with anti-phospho-Tyr705 STAT3 antibody (Ab) or with con-
trol rabbit IgG. In Figure 1a, panels A–C ( 10) and D–F
(20), activation of phospho-STAT3 was confirmed by the
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Figure 1. Activation of phospho-signal transducer and activator of transcription (STAT3) in post-burn hypertrophic scar (HS). (a) Immunohistochemical analysis
of phospho-STAT3 (Tyr 705) expression in burned HS skin. A–F and G are HS skin stained with anti-phosphoTyr705-STAT3 Ab and control IgG, respectively.
Panels H and I are normal skin stained with anti-phosphoTyr705-STAT3 Ab. Arrowheads (D–F) show the strong nuclear staining for activated STAT3. A–C, G–H,
and D–F, I are  10 and  20 magnifications, respectively, bar¼10mm. (b) Intensity of nuclear staining in the dermis of HS (n¼10) and normal skin (n¼ 5)
(MetaMorph 7.3). *Po0.01. (c) Western Immunoblot analysis of phospho-STAT3 (Tyr 705) in HS fibroblasts (HSFs). Whole-cell extracts of normal fibroblast (NF)
and HSF were fractionated and western immunoblot analysis with phospho-STAT3 (Tyr 705) Ab is shown. The numbers at the bottom of the lane indicate the fold
induction. b-Actin blot (lower panel) shows loading control. IB, immunoblotting.
S Ray et al.
Role of IL-6 Trans-Signaling-STAT3 Pathway in HS
www.jidonline.org 1213
presence of positive nuclear staining for phospho-Tyr705
STAT3 in the dermal fibroblast nuclei of burned skin with
HS. Staining of HS skin with rabbit IgG (panel G) and normal
skin with phospho-Tyr705 STAT3 Ab (panel H–I) did not show
any significant nuclear staining in the dermis, indicating
specificity of the phopho-Tyr705 STAT3 Ab and upregulation
of phospho-STAT3 in HS. Increased dermal-staining intensity
was measured in HS and is shown in Figure 1b.
Further, we determined the induction of activated STAT3 in
primary HS fibroblast (HSF) derived from burned patient with
severe HS and in NF derived from the nonburned area of the
same patient. We first confirmed the presence of fibroblast
cells in the postburn HSF by staining with fibroblast marker a-
smooth muscle actin (a-SMA) Ab and also measuring a-SMA
gene expression by reverse-transcriptase–PCR. The supporting
data (Supplementary Figure S1 online) show a high level of
immunoflurescence staining in HSF with a-SMA Ab and
upregulated a-SMA gene expression in HSF compared with
NF (Supplementary Figure S2 online). Furthermore, we per-
formed the western immunoblot analysis of whole-cell extract
isolated from HSF and NF with phopho-Tyr705 STAT3 Ab. In
Figure 1c, upper panel, we observed that, in contrast to NFs,
HSFs showed a 2-fold increase in phospho-STAT3 signal,
indicating that STAT3 activation occurs in HS. The lower
panel shows b-actin expression as loading control. Activation
of phospho-STAT3, confirmed by western blot, by other HSFs
is presented in supporting Supplementary Figure S3 online.
Activation of STAT3 target gene in HSF by the IL-6
trans-signaling pathway
As NF cells do not express membrane-bound IL-6Ra, we
hypothesized that STAT3 could be activated in HS through the
IL-6 trans-signaling pathway. Here, we either treated the NF
and HSF cells with IL-6sIL-6Ra or left them untreated and
measured expression of the STAT3-regulated human suppres-
sor of cytokine signaling (hSOCS3) gene in total RNA using
quantitative real-time reverse-transcriptase–PCR (QRT-PCR).
In contrast to NFs, hSOCS3 expression in HSFs was induced
both under basal conditions and in response to IL-6sIL-6Ra
(Figure 2a), indicating that HSFs have enhanced sensitivity to
IL-6 trans-signaling. We also measured the kinetics of acti-
vated STAT3 expression in the HSF and NF cells in the
presence of IL-6sIL-6Ra by a quantitative bioplex phospho-
protein detection assay. We observed that phospho-Tyr705
STAT3 expression is higher in HSF than in NF and peaked
(B2.5-fold) at 30 min after IL-6sIL-6Ra stimulation, which
gradually decreased after 60 min (data not shown). To prove
the involvement of STAT3 in HSF sensitivity to IL-6 trans-
signaling, the effect of reducing endogenous STAT3 level was
investigated. For this purpose, RNA interference was used to
reduce STAT3 expression in HSFs and NFs, where activated
STAT3 levels were reduced by 470% with STAT3 siRNA as
compared with cells transfected with nontarget control siRNA,
Figure 2b. In Figure 2c, hSOCS3 gene expression was
attenuated in the presence of STAT3 siRNA indicating the
role of STAT3 in target gene activation during HS formation.
Enhanced STAT3 recruitment to the hSOCS3 promoter in HSF
To establish that enhanced sensitivity of HSF to IL-6 trans-
signaling is because of the increased STAT3 recruitment on its
target hSOCS3 promoter, we used a two-step chromatin
immunoprecipitation (ChIP) assay on chromatin isolated from
IL-6sIL-6Ra–stimulated NFs and HSFs. Figure 3 shows that in
the presence of IL-6sIL-6Ra, the promoter abundance of
STAT3 is significantly increased in HSFs compared with that in
NFs. This result indicates that the increased STAT3 occupancy
in HSF is required for enhanced target gene expression and
sensitivity to IL-6 trans-signaling.
Increased expression of cell-surface gp130 in HSF
Gp130 is the upstream rate-limiting signal transducer of
the IL-6sIL-6Ra complex. To evaluate the possibility that
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Figure 2. Activation of STAT3 target gave by IL-6 trans-signaling pathway in hypertrophic scar fibroblast (HSF). (a) Activation of IL-6 trans-signaling in HSF.
Normal fibroblast (NF) and HSF cells were either treated with IL-6soluble IL-6Ra (sIL-6Ra) (8 ng ml 125 ng ml1) for 30 min or left untreated. Total cellular RNA
was subjected to quantitative real-time reverse-transcriptase–PCR (QRT-PCR) for human suppressor of cytokine signaling (hSOCS)3 transcript. Shown is
fold-change messenger RNA (mRNA) expression relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Data represent the mean±SD, *Po0.01.
(b) Inhibition of phospho-signal transducer and activator of transcription (STAT)3 with STAT3 small interfering RNA (siRNA). NFs and HSFs were transfected with
either control or STAT3 siRNA. At 72 h after transfection, cells were stimulated as above and whole-cell extracts were measured for phosphoTry705-STAT3 by
immunoassay (Bio-Rad). Shown is the representative fluorescence intensity of phospho-STAT3 relative to total protein. (c) Inhibition of hSOCS3 gene with STAT3
silencing. Cells were treated as in (b) and total cellular RNA was subjected to QRT-PCR for hSOCS3 expression relative to GAPDH. *Po0.05. MFI, mean
fluorescence intensity.
S Ray et al.
Role of IL-6 Trans-Signaling-STAT3 Pathway in HS
1214 Journal of Investigative Dermatology (2013), Volume 133
the increased trans-signaling seen in HSFs is because of the
upregulation of the gp130 (O’Brien and Manolagas, 1997),
gp130 mRNA was measured by QRT-PCR in IL-6sIL-6Ra–
stimulated NF and HSF cells. We observed increased levels of
gp130 transcript (B3-fold) in HSF compared with NF,
explaining the exaggerated response of HSF cells to IL-6sIL-
6Ra (Figure 4a). We further analyzed the cell-surface expres-
sion of gp130 by flow cytometry in IL-6sIL-6Ra–stimulated
HSF and NF cells. In Figure 4b, flow cytometry data showed
increase in the mean fluorescence intensity of gp130-phycoer-
ythrin in HSF cells from 965 to 1692 arbitrary units when
stimulated with IL-6sIL-6Ra. Further, there are significantly
higher amounts of gp130-expressing HSF cells (B60%) than NF
cells under stimulated conditions. These exciting findings sug-
gest that HSFs have upregulated gp130 expression and thereby
show enhanced sensitivity to the IL-6 trans-signaling pathway.
STAT3 inhibitor abrogates production of ECM in HSF
To test that high STAT3 activation in post-burn HS upregulates
ECM gene expression, we examined ECM production in
HSFs and NFs. We measured the mRNA expression of
alpha2 (I) procollagen (Col1A2) and fibronectin 1 (FN), two
principal ECM molecules involved in keloid formation
(Ghazizadeh et al., 2007). Total cellular RNA was isolated,
and expression of the STAT3-regulated human Col1A2 and FN
genes was measured by QRT-PCR. In, Figure 5a, contrast to
NFs, expression of Col1A2 and FN genes was induced in
HSFs, indicating increased ECM production. To investigate the
functional role of STAT3 in ECM synthesis, we used a cell-
permeable STAT3 peptide inhibitor previously reported to
inhibit STAT3 but not STAT1 (Timofeeva et al., 2007). For this
purpose, we first determined the effect of this peptide on
hSOCS3 expression. We treated NFs and HSFs with the STAT3
inhibitor peptide (500 nM) for 6 hours, and stimulated with
IL-6sIL-6Ra for 30 minute before harvest. Total RNA was then
subjected to QRT-PCR for the hSOCS3 gene. As seen in Figure
5b, the inhibitor peptide had very little or no effect on NFs,
whereas in HSFs induction of the hSOCS3 gene was abrogated
in the presence of the peptide, indicating a role of activated
STAT3 in HSFs. We next examined the effect of this STAT3
inhibitor on FN and Col1A2 gene expression. In contrast to
NFs, inhibitor treatment of HSFs abrogated the expression of
3.5
3.0
2.5
2.0
0.5
0
NF
NF100
80
Comp-PE-A-
76.15
Comp-PE-A-
16.81
Comp-PE-A+
23.85
Comp-PE-A+
83.19
60
40C
ou
nt
20
0 102 103
Fluorescence intensity
104 105 0 102 103 104 105
100
Iso
Unstimulated
Stimulated
80
60
40
20
HSF
HSF
1.0
*
1.5
gp
13
0 
Ex
pr
es
sio
n 
(fo
ld 
ch
an
ge
)
a b
Figure 4. Activation of cell-surface signal transducer, gp130 in hypertrophic scar fibroblast (HSF). (a) Activation of glycoprotein 130 (gp130) in hypertrophic scar
fibroblast (HSF). Normal fibroblasts (NFs) and HSFs were treated with IL-6soluble IL-6Ra (sIL-6Ra) for 30 min. Total RNA was subjected to quantitative real-time
reverse-transcriptase–PCR for human gp130 messenger RNA (mRNA) expression, and performed in triplicates. Shown is fold-change mRNA expression relative to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as internal control. Data represent the mean±SD. *Po0.01, Student’s t-test. (b) Cell-surface activation of
gp130 in HSF. Cultured NF and HSF cells were left untreated or IL-6sIL-6Ra (8 ng ml1 25 ng ml 1) stimulated for 30 min. The expression of cell-surface gp130
was analyzed by flow cytometry after staining with anti-gp130-phycoerythrin (PE). Events were plotted as a function of fluorescence intensity (x-axis). Shaded
histograms represent isotype antibody control and open histograms represent either unstimulated anti-gp130-PE-stained cells (dotted line) or IL-6sIL-6 Ra–
stimulated anti-gp130-PE (solid line) as indicated.
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Figure 3. Human suppressor of cytokine signaling (hSOCS)3 promoter
occupancy of signal transducer and activator of transcription (STAT)3 in
hypertrophic scar fibroblast (HSF) and normal fibroblast (NF). Protein–DNA
cross-linked extracts of IL-6soluble IL-6Ra (sIL-6Ra) (8 ng ml1 25 ng ml 1)
stimulated NF and HSF cells were immunoprecipitated with IgG or anti-STAT3
Ab. SOCS3 promoter occupancy of STAT3 were detected by the two-step
chromatin immunoprecipitation assays as described in the Materials and
Methods. Shown is the fold change in quantitative genomic PCR (Q-gPCR)
normalized to input DNA. *Po0.01, Student’s t-test.
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IL-6sIL-6Ra-induced FN (Figure 5c) and Col1A2 (Figure 5d)
gene expression, indicating the requirement for STAT3 in ECM
production in post-burn HS.
Requirement for STAT3 in the increased proliferation of HSFs
STAT3’s role in fibroblast proliferation following a burn injury
is incompletely understood. Previous work has shown that
fibroblasts from burned patients with keloids have increased
growth rates compared with nonlesion fibroblasts
(Ghazizadeh et al., 2007). As we also observed a
similar higher growth rate in postburned HSF than in NF
(Supplementary Figure S4 online), here we measured the
expression of cellular proliferation marker Cyclin D1,
c-Myc, and Bcl-xl in HSFs and NFs. As expected, mRNA
expression of Cyclin D1, c-Myc, and Bcl-xL genes were
upregulated in HSFs as compared with NFs indicating exag-
gerated fibroblast proliferation associated with scar formation
(Figure 6a). To assess the direct effect of STAT3 in HSF
proliferation, cells were transfected with STAT3 siRNA or
nontarget control siRNA, and total RNA was extracted for
c-Myc expression. In Figure 6b, a significant decrease in
c-Myc expression was observed in NF and HSF cells in the
presence of STAT3 siRNA indicating the role of STAT3
activation in ECM synthesis and cellular proliferation, con-
tributing to HS pathogenesis.
DISCUSSION
The systemic inflammatory response after burn injury releases
large quantities of proinflammatory cytokines, including IL-6
(Finnerty et al., 2008). In macrophage-inflamed tissues, a
soluble IL-6 receptor (sIL-6Ra) is formed, which when bound
to IL-6 acts as an agonist on dermal fibroblasts that express the
cell-surface signal transducer gp130. Binding of IL-6sIL-6Ra
to gp130 activates the transcription factor STAT3 through the
IL-6 trans-signaling pathway, a pathway known to be crucial
in the pathogenesis of inflammatory diseases (Jones et al.,
2005). The pathophysiology of HS, characterized by fibroblast
proliferation and excessive collagen deposition, remains
largely unknown. Although few studies have shown that
cytokines, especially IL-6, have an important role in the
pathogenesis of keloid scar (Lim et al., 2006; Ghazizadeh
et al., 2007), activation of the IL-6 trans-signaling-gp130-
STAT3 pathway and its downstream functional roles in the
pathogenesis of HS has not been documented. In this study,
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Figure 5. Requirement of signal transducer and activator of transcription (STAT3) in ECM production in hypertrophic scar fibroblast (HSF). (a) Extracellular
matrix expression in HSF. Normal fibroblasts (NFs) and HSFs were stimulated with IL-6soluble IL-6Ra (sIL-6Ra) and total cellular RNA was subjected to
quantitative real-time reverse-transcriptase–PCR (QRT-PCR) for Col1A2 and fibronectin 1 (FN) expression. Shown is fold-change messenger RNA (mRNA)
expression relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). *Po0.01. (b) STAT3 peptide inhibitor attenuates human suppressor of cytokine
signaling (hSOCS)3 expression. NFs and HSFs were treated with 500 nM STAT3 inhibitor peptide for 6 h or left untreated. Total cellular RNA (stimulated) was
subjected to QRT-PCR for hSOCS3 transcript. *Po0.01. (c) STAT3 peptide inhibitor abrogates FN production in HSF. Cells were treated as in (b) and FN gene
expression was measured relative to GAPDH. *Po0.05. (d) STAT3 peptide inhibitor abrogates Col1A2 production in HSF. Cells were treated as in (b) and Col1A2
gene expression was measured relative to GAPDH. *Po0.05.
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we have established the activation of gp130-STAT3 signaling
through an IL-6 trans-signaling pathway in HSFs. Our data
show that activation of STAT3 leads to upregulation of STAT3
target genes including those controlling ECM production and
cellular proliferation, and may also regulate the upstream
signal transducer gp130. Activation of these genes by
increased STAT3 occupancy in their promoter leads to
abnormal wound healing, excessive collagen deposition, and
fibroproliferative growth in HS lesions.
The key element of this study is the transcription factor
STAT3, which we showed by IHC, being activated by tyrosine
phosphorylation in human HS tissue sections. Dermal fibro-
blasts are the main regulatory cells that are known to increase
in HS lesions by secreting collagen, cytokines, and chemo-
kines. These secreted molecules induce fibroblast proliferation
and migration of inflammatory cells leading to fibrosis
(Sidgwick and Bayat, 2012). Although dermal fibroblast cells
are known to produce a large amount of IL-6, several studies
have shown that they do not express enough membrane-
bound IL-6Ra, and they are thought to respond to IL-6 mainly
through the IL-6 trans-signaling pathway (Sporri et al., 1999;
Jones et al., 2005). This information led us to test our
hypothesis that activation of STAT3 in HS occurs through
the IL-6 trans-signaling pathway. Our observation that
addition of IL-6sIL-6Ra stimulated STAT3 phosphorylation
in primary HSF and concomitant activation of STAT3 target
gene in vitro supports our hypothesis that activation of STAT3
in HS may also act in vivo by the IL-6 trans-signaling pathway.
Formation of the IL-6sIL-6Ra complex initiates transduc-
tion through the membrane-bound gp130 signal transducer
leading to the activation of the JAK–STAT3 signaling path-
ways. Gp130 is a shared receptor for the IL-6 cytokine family
and so modulation of gp130 synthesis by its ligands may serve
to replenish receptor consumption. Our QRT-PCR and FACS
analyses showed upregulation of gp130 expression and
increased cell-surface gp130 in HSFs explaining the exagger-
ated response of HSF to stimulation by the IL-6sIL-6Ra. IL-
6sIL-6Ra has not been previously shown to regulate gp130 or
gp130 posttranslational processing. However, (O’Brien and
Manolagas, 1997) a previous study confirmed the presence of
a STAT3 response element in the gp130 promoter. Thus,
consistent with this study on HSF, robust activation of STAT3
by IL-6 trans-signaling promotes increased gp130 transcription
and protein expression, and therefore IL-6sIL-6Ra-STAT3-
gp130 may act in a positive feedback loop.
STAT3 is a transcription factor that affects promoter activity
of its target gene by binding to a specific cis-element (Ray
et al., 2010). Using a ChIP assay, we provide direct evidence
that increased binding of STAT3 to hSOCS3 promoter in HSF
leads to enhanced hSOCS3 expression. We previously showed
that STAT3 is acetylated as a direct target of the p300
coactivator in vivo and in vitro (Eckner et al., 1994; Ray
et al., 2005), and this modification induces STAT3 binding to
CDK-9, a member of the positive transcription elongation
factor-b (Hou et al., 2007; Hou et al., 2008a). The role of
STAT3 acetylation and recruitment of positive transcription
elongation factor-b in understanding gene regulation in HSFs
will be studied in future.
The ultimate fate of HS is the exuberant synthesis, deposi-
tion, and remodeling of the ECM by fibroblast cells, leading to
fibrosis. HSFs and Keloid fibroblasts are known to produce
excessively many types of ECM, such as Collagen type I and
VI as well as fibronectin (Abergel et al., 1985; Sidgwick and
Bayat, 2012). We report here that STAT3 has a major role in
the excessive collagen deposition by fibroblasts, leading to
HS. Inhibition of STAT3 by a cell-permeable STAT3 inhibitor
showed a corresponding decline in collagen and fibronectin
expression, suggesting that ECM production may be regulated
by STAT3 at the transcription level.
Fibroproliferation is the characteristic of HS and Keloids that
is known to involve the overgrowth of fibroblast (Ghazizadeh
et al., 2007; Lim et al., 2009; Matsui et al., 2011). Although a
large body of work has shown that STAT3 promotes
proliferation by its role as a transcription factor, inducing
expression of oncogenes, cell cycle regulatory genes, and
antiapoptotic genes (Sinibaldi et al., 2000; Bowman et al.,
2001; Haga et al., 2003), the IL-6–STAT3 pathway may not be
the only pathway controlling this process. Tao et al., 2010
have observed involvement of JAK–STAT1 pathway in pro-
liferation and differentiation of HSF by CTGF, which is a
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Figure 6. Signal transducer and activator of transcription (STAT3) augments cellular proliferation marker expression in hypertrophic scar fibroblast (HSF).
(a) IL-6 trans-signaling increases expression of cellular proliferation markers in HSF. Normal fibroblast (NF) and HSF cells were stimulated with IL-6soluble IL-6Ra
(sIL-6Ra) and total cellular RNA was subjected to quantitative PCR (QPCR) for c-Myc, Bcl-XL, and Cyclin D1 gene expression. Shown is fold-change messenger
RNA expression relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as internal control performed in triplicates. Data represent the mean±SD.
*Po0.05, Student’s t-test. (b) STAT3 small interfering RNA (siRNA) inhibits expression of cellular proliferation markers in HSF. NF and HSF cells were transfected
with either STAT3 siRNA or control siRNA. Transfected cells were stimulated with IL-6sIL-6Ra for 30 min after 72 h, and total cellular RNA was subjected
to QPCR for c-Myc gene expression. *Po0.01, Student’s t-test.
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downstream mediator of TGFb1 and has been widely impli-
cated in wound healing, scarring, and tissue fibrosis (Igarashi
et al., 1996; Penn et al., 2012; Zunwen et al., 2012). Here, our
observation of enhanced expression of proliferation marker
Cycline D1, c-Myc, and Bcl-XL in HSFs and attenuation of
cellular proliferation genes by STAT3 siRNA showed a direct
role for STAT3 in the fibroproliferation of HS.
In summary, we have shown that STAT3 is activated in HS
by IL-6 trans-signaling pathways that mediate ECM production
and dermal fibroblast proliferation. These results elucidate the
signal transduction mechanism by STAT3 in HS and therefore
may aid in the development of STAT3 antagonists as transla-
tional therapies for burn-induced scarring. The development
of a nontoxic, topical therapy to decrease HS would signifi-
cantly benefit the one million people suffering from burn
injuries annually, by negating the need for repeated surgeries
and thereby improving the long-term quality of life.
MATERIALS AND METHODS
Cell culture and tissue biopsies
Skin and scar biopsies were acquired during scar revision surgeries
performed between 6 and 21 months postburn. Samples
were immediately stored in formalin for paraffin embedding or in
15% fetal calf serum in DMEM with 1% penicillin–streptomycin
sulfate-amphotericin B for fibroblast isolation as described previously
(Zhang et al., 2011). Patients enrolled in the study were between 0
and 18 years of age at the time of injury with at least 30% of the total
body surface area burned and requiring at least one operative
intervention. This study was part of a large clinical trial
(www.clinicaltrials.gov, NCT00675714) evaluating the outcomes of
burn survivors. The study protocol and informed consent were in
compliance with Declaration of Helsinki Principles and was
approved by the Institutional Review Board of The University of
Texas Medical Branch (Galveston, TX). In this study, we have used 10
HS-tissue biopsies for IHC and all experiments with primary
fibroblasts (HSF and NF) were conducted on three-patient samples
at passages 3–7.
Reagents and antibodies
Sources of primary antibody (Ab) for the ChIP assay and western Blot
included Santa Cruz Biotechnology (Santa Cruz, CA) anti-STAT3 C20
and anti-phospho-Tyr STAT3 B7 Ab, respectively. For IHC, we used
Phospho-STAT3 (Tyr 705)(D3A7)XP mAb from New England Bio Labs
(Ipswich, MA).
Recombinant human IL-6 and sIL-6Ra were obtained from Pepro
Tech (Rocky Hill, NJ).
Cell-permeable STAT3 peptide inhibitor (STAT3-Hel2a-Penetratin)
was synthesized at UTMB Protein Chemistry laboratory.
Western blot analysis
Whole-cell extracts were prepared by lysing NFs and HSFs in
modified RIPA buffer, and fractionated by 10% SDS-PAGE as
previously described (Ray et al., 2008).
Immunohistochemistry
Activated STAT3 was detected on paraffin-embedded HS tissues using
Phospho-STAT3 (Tyr 705)(D3A7)XP Rabbit mAb from New England
Bio Labs following the manufacturer’s protocol.
Bio-Plex phosphoprotein detection
Phospho-Tyr705 STAT3 was detected in NFs and HSFs with a Bio-
Rad (Hercules, CA) phosphoprotein immunoassay kit using the Bio-
Plex 100 sysytem, according to the manufacture’s protocol. Data
analysis was performed using Bio-Plex Manager software version 5.
siRNA transfection
STAT3 siRNA (Dharmacon, Waltham, MA) were transfected in NFs
and HSFs (70% confluent) by TransIT-siQUEST transfection reagent
(Mirus, Madison, WI) at 75 nmol l 1 final concentration following
manufacturer’s instructions. Transfected cells were stimulated in serum-
free media after 72 h and harvested for protein or total RNA extraction.
Quantitative real-time PCR
Total cellular RNA after extraction with Tri Reagent (Sigma, St Louis,
MO) was subjected to reverse transcription using an iScript cDNA Kit
(Bio-Rad). Complementary DNA products were amplified in a 20-ml
reaction volume containing 10ml iQ SYBR Green Super Mix (Bio-
Rad) and 400 nM primer as previously described (Ray et al., 2010).
To normalize template input, glyceraldehyde-3-phosphate
dehydrogenase transcript level was measured for each sample. Data
are expressed as fold change after normalizing to glyceraldehyde-3-
phosphate dehydrogenase. The human primers used for reverse-
transcriptase–PCR are as follows: FN, sense primer (SP): 50-GCG
CCGGCTGTGCTGCACAGG-30 and anti-sense primer (AS): 50-GCCT
GGGGACAGCGGTGCCC-30; Col1A2, SP: 50-CAGCCCCGTGGCCA
CGTCCC-30 and AS: 50-CCACAGGCCCTCCTGGTCCA-30; Cyclin
D1, SP: 50-GTGCTGCGAAGTGGAAACC-30 and AS: 50-ATCCAGGT
GGCGACGATCT-30; c-Myc, SP: 50-ATTCTCTGCTCTCCTCGA-30 and
AS: 50-TCTTGGCAGCAGGATAGT-30; Bcl-xl, SP: 50-GTTGAAGCGTT
CCTGGCCCTTT-30 and AS: 50-CAGAATGGACTGAATCGGAGAT-30;
SOCS3, SP: 50-CAAGGACGGAGACTTCGATT-30 and AS: 50-GACTG
GGTCTTGACGCTGA-30 and Gp130, SP: 50-CTGTATCACAGACTGG
CAACAAG-30 and AS: 50-GCATTTGCTCTCTGCTAAGTTCC-30.
Flow cytometry
Cultured NFs and HSFs, after IL-6sIL-6Ra stimulation, were
harvested with 1 mM EDTA in phosphate-buffered saline and washed
with FACS buffer as previously described (Tieu et al., 2009). Cells
were Fc-blocked using purified human IgG and then either incubated
with fluorescence-conjugated anti-human gp130-phycoerythrin
antibody (R&D Systems, Minneapolis, MN; FAB228P) or
corresponding isotype control Ab (R&D systems, IC002P) according
to the manufactures’s instruction. Samples were analyzed by FACS
Canto (BD, Sparks, MD) and data were analyzed with FlowJo
software (Ashland, OR).
ChIP assay
Two-step ChIP was performed with 4–6 106 NF and HSF cells, after
IL-6sIL-6Ra stimulation as previously described (Nowak et al.,
2005). The promoter-specific primers used for quantitative genomic
PCR for hSOCS3 are, SP: 50-AGCCTTTCTCTGCTGCGAGT-30 and AS:
50-AGCAGGGAGTCCAAGTCG-30.
Statistical analysis
Experiments were performed in triplicates and the data are expressed
as mean±SD. Statistical analysis was performed using the two-tailed
Student’s t-test, with significance set at Po0.05.
S Ray et al.
Role of IL-6 Trans-Signaling-STAT3 Pathway in HS
1218 Journal of Investigative Dermatology (2013), Volume 133
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
This work was supported by National Heart Lung and Blood Institute R01
HL070925 (to ARB) and a Clinical and Translational Science Award
(UL1RR029876 to ARB). This study was supported by grants from the National
Institute for Disabilities and Rehabilitation Research (H133A070026 and
H133A70019) (DNH), the National Institutes of Health (P50-GM60338, R01-
HD049471, and T32-GM8256) (DNH), the Shriners Hospitals for Children
(84080 to DNH; 8740 and 71001 to CCF), and the Wound Healing Society
Foundation (CCF). CCF is an ITS Career Development Scholar supported, in
part, by NIH KL2RR029875 and NIH UL1RR029876. This study is registered at
clinicaltrials.gov, NCT00675714.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at http://
www.nature.com/jid
REFERENCES
Abergel RP, Pizzurro D, Meeker CA et al. (1985) Biochemical composition of
the connective tissue in keloids and analysis of collagen metabolism in
keloid fibroblast cultures. J Invest Dermatol 84:384–90
Bombaro KM, Engrav LH, Carrougher GJ et al. (2003) What is the
prevalence of hypertrophic scarring following burns? Burns 29:
299–302
Bowman T, Broome MA, Sinibaldi D et al. (2001) Stat3-mediated Myc
expression is required for Src transformation and PDGF-induced mitogen-
esis. Proc Natl Acad Sci USA 98:7319–24
Castagnoli C, Trombotto C, Ondei S et al. (1997) Characterization
of T-cell subsets infiltrating post-burn hypertrophic scar tissues. Burns
23:565–72
Dauer DJ, Ferraro B, Song LX et al. (2005) Stat3 regulates genes common to
both wound healing and cancer. Oncogene 24:3397–408
Deitch EA, Wheelahan TM, Rose MP et al. (1983) Hypertrophic burn scars:
analysis of variables. J Trauma 23:895–8
Ebihara N, Matsuda A, Nakamura S et al. (2011) Role of the IL-6 classic- and
trans-signaling pathways in corneal sterile inflammation and wound
healing. Invest Ophthalmol Vis Sci 52:8549–57
Eckner R, Ewen ME, Newsome D et al. (1994) Molecular cloning and
functional ananlysis of the adenovirus E1A-associated 300 kD protein
(p300) reveals a protein with properties of a transcriptional adaptor.
Genes Dev 8:869–84
Feghali CA, Bost KL, Boulware DW et al. (1994) Control of IL-6 expression and
response in fibroblasts from patients with systemic sclerosis. Autoimmu-
nity 17:309–18
Finnerty CC, Herndon DN, Przkora R et al. (2006) Cytokine expression profile
over time in severely burned pediatric patients. Shock 26:13–9
Finnerty CC, Jeschke MG, Herndon DN et al. (2008) Temporal cytokine
profiles in severely burned patients: a comparison of adults and children.
Mol Med 14:553–60
Ghazizadeh M, Tosa M, Shimizu H et al. (2007) Functional implications of the
IL-6 signaling pathway in keloid pathogenesis. J Invest Dermatol 127:
98–105
Haga S, Terui K, Zhang HQ et al. (2003) Stat3 protects against Fas-induced
liver injury by redox-dependent and -independent mechanisms. J Clin
Invest 112:989–98
Hou T, Ray S, Brasier AR (2007) The functional role of an interleukin 6-
inducible CDK9.STAT3 complex in human gamma-fibrinogen gene
expression. J Biol Chem 282:37091–102
Hou T, Ray S, Lee C et al. (2008a) The STAT3 NH2-terminal domain stabilizes
enhanceosome assembly by interacting with the p300 bromodomain.
J Biol Chem 283:30725–34
Hou T, Tieu BC, Ray S et al. (2008b) Roles of IL-6-gp130 Signaling in Vascular
Inflammation. Curr Cardiol Rev 4:179–92
Igarashi A, Nashiro K, Kikuchi K et al. (1996) Connective tissue
growth factor gene expression in tissue sections from localized scler-
oderma, keloid, and other fibrotic skin disorders. J Invest Dermatol
106:729–33
Jeschke MG, Chinkes DL, Finnerty CC et al. (2008) Pathophysiologic response
to severe burn injury. Ann Surg 248:387–401
Jones SA, Horiuchi S, Topley N et al. (2001) The soluble interleukin
6 receptor: mechanisms of production and implications in disease. FASEB
J 15:43–58
Jones SA, Richards PJ, Scheller J et al. (2005) IL-6 transsignaling: the in vivo
consequences. J Interferon Cytokine Res 25:241–53
Kushner I (1988) The acute phase response: an overview. Methods Enzymol
163:373–83
Lim CP, Phan TT, Lim IJ et al. (2006) Stat3 contributes to keloid pathogenesis
via promoting collagen production, cell proliferation and migration.
Oncogene 25:5416–25
Lim CP, Phan TT, Lim IJ et al. (2009) Cytokine profiling and Stat3 phosphor-
ylation in epithelial-mesenchymal interactions between keloid keratino-
cytes and fibroblasts. J Invest Dermatol 129:851–61
Matsui T, Ito C, Oda M et al. (2011) Lapachol suppresses cell proliferation
and secretion of interleukin-6 and plasminogen activator inhibitor-1
of fibroblasts derived from hypertrophic scars. J Pharm Pharmacol
63:960–6
Nowak DE, Tian B, Brasier AR (2005) Two-step cross-linking method for
identification of NF-kappaB gene network by chromatin immunoprecipi-
tation. Biotechniques 39:715–25
O’Brien CA, Manolagas SC (1997) Isolation and characterization of
the human gp130 promoter. Regulation by STATS. J Biol Chem
272:15003–10
Penn JW, Grobbelaar AO, Rolfe KJ (2012) The role of the TGF-b
family in wound healing, burns and scarring: a review. Int J Burns Trauma
2:18–28
Ray S, Boldogh I, Brasier AR (2005) STAT3 NH2-terminal
acetylation is activated by the hepatic acute-phase response and
required for IL-6 induction of angiotensinogen. Gastroenterology
129:1616–32
Ray S, Lee C, Hou T et al. (2010) Regulation of signal transducer and activator
of transcription 3 enhanceosome formation by apurinic/apyrimidinic
endonuclease 1 in hepatic acute phase response. Mol Endocrinol
24:391–401
Ray S, Lee C, Hou T et al. (2008) Requirement of histone deacetylase1
(HDAC1) in signal transducer and activator of transcription 3 (STAT3)
nucleocytoplasmic distribution. Nucleic Acids Res 36:4510–20
Sano S, Chan KS, Digiovanni J (2008) Impact of Stat3 activation upon skin
biology: a dichotomy of its role between homeostasis and diseases.
J Dermatol Sci 50:1–14
Scheller J, Rose-John S (2006) Updating interleukin-6 classic- and trans-
signaling. Signal Transduct 6:240–59
Scott PG, Ghahary A, Tredget EE (2000) Molecular and cellular aspects of
fibrosis following thermal injury. Hand Clin 16:271–87
Shahar I, Fireman E, Topilsky M et al. (1996) Effect of IL-6 on alveolar fibroblast
proliferation in interstitial lung diseases. Clin Immunol Immunopathol
79:244–51
Sheridan RL, Tompkins RG (2004) What’s new in burns and metabolism. J Am
Coll Surg 198:243–63
Sidgwick GP, Bayat A (2012) Extracellular matrix molecules implicated
in hypertrophic and keloid scarring. J Eur Acad Dermatol Venereol
26:141–52
Sinibaldi D, Wharton W, Turkson J et al. (2000) Induction of p21WAF1/CIP1
and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts:
role of activated STAT3 signaling. Oncogene 19:5419–27
Sporri B, Muller KM, Wiesmann U et al. (1999) Soluble IL-6 receptor induces
calcium flux and selectively modulates chemokine expression in human
dermal fibroblasts. Int Immunol 11:1053–8
Tan PL, Farmiloe S, Yeoman S et al. (1990) Expression of the interleukin 6 gene
in rheumatoid synovial fibroblasts. J Rheumatol 17:1608–12
S Ray et al.
Role of IL-6 Trans-Signaling-STAT3 Pathway in HS
www.jidonline.org 1219
Tao L, Liu J, Li Z et al. (2010) Role of the JAK-STAT pathway in proliferation
and differentiation of human hypertrophic scar fibroblasts induced by
connective tissue growth factor. Mol Med Report 3:941–5
Tieu BC, Lee C, Sun H et al. (2009) An adventitial IL-6/MCP1 amplification
loop accelerates macrophage-mediated vascular inflammation leading to
aortic dissection in mice. J Clin Invest 119:3637–51
Timofeeva OA, Gaponenko V, Lockett SJ et al. (2007) Rationally designed
inhibitors identify STAT3 N-domain as a promising anticancer drug target.
ACS Chem Biol 2:799–809
van Zuijlen PP, Vloemans JF, van Trier AJ et al. (2001) Dermal substitution in
acute burns and reconstructive surgery: a subjective and objective long-
term follow-up. Plast Reconstr Surg 108:1938–46
Vermes C, Jacobs JJ, Zhang J et al. (2002) Shedding of the inter-
leukin-6 (IL-6) receptor (gp80) determines the ability of IL-6
to induce gp130 phosphorylation in human osteoblasts. J Biol Chem
277:16879–87
Yamauchi-Takihara K, Kishimoto T (2000) A role for STAT3 in cardiac
remodeling. Trends Cardiovasc Med 10:298–303
Zhang Z, Finnerty CC, He J et al. (2011) Smad ubiquitination regulatory factor
2 expression is enhanced in hypertrophic scar fibroblasts from burned
children. Burns 38:236–46
Zunwen L, Shizhen Z, Dewu L et al. (2012) Effect of tetrandrine on the TGF-b-
induced smad signal transduction pathway in human hypertrophic scar
fibroblasts in vitro. Burns 38:404–13
S Ray et al.
Role of IL-6 Trans-Signaling-STAT3 Pathway in HS
1220 Journal of Investigative Dermatology (2013), Volume 133
